佐替平

C₁₈H₁₈ClNOS

331.86

MFCD00868143

329831602

NA.77

Zotepine has been used as an anti-psychotic agent:

• in biophysical studies with serotonin 2A receptor (5-HT_2AR)
• to study its effects on the inhibition of human organic cation transporter 1 (hOCT1)
• to study its protective effects on the human embryonic kidney (HEK cells)

Zotepine acts as an antagonist of dopamine D1, D2, and serotonin (5-HT_2A/2C) receptors, and noradrenaline transporters. It shows therapeutic effects against schizophrenia and acute mania.
Zotepine is an atypical antipsychotic.

This compound was developed by Astellas. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. Z0877.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

>98% (HPLC)

100

powder

white to off-white

DMSO: ≥20 mg/mL

Astellas

room temp

CN(C)CCOC1=Cc2ccccc2Sc3ccc(Cl)cc13

1S/C18H18ClNOS/c1-20(2)9-10-21-16-11-13-5-3-4-6-17(13)22-18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3

HDOZVRUNCMBHFH-UHFFFAOYSA-N

10, 50 mg in glass bottle

GHS07,GHS09

Warning

H302 - H400

P273

Acute Tox. 4 Oral - Aquatic Acute 1

6.1D - Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

WGK 3